Trametinib Induces the Stabilization of a Dual GNAQ p.Gly48Leu- and FGFR4 p.Cys172Gly-Mutated Uveal Melanoma. The Role of Molecular Modelling in Personalized Oncology

Autor: Veronica Aedo-Lopez, Bettina Bisig, Alexandre Wicky, Olivier Michielin, Mounir Trimech, Camille L. Gerard, Fanny S Krebs, Krisztian Homicsko, Edoardo Missiaglia, Vincent Zoete
Jazyk: angličtina
Rok vydání: 2020
Předmět:
Models
Molecular

Uveal Neoplasms
Protein Conformation
Sequence Homology
medicine.disease_cause
lcsh:Chemistry
Melanoma
lcsh:QH301-705.5
Spectroscopy
Trametinib
Mutation
biology
Chemistry
Protein Stability
MEK inhibitor
General Medicine
Middle Aged
Computer Science Applications
molecular modelling
Gq alpha subunit
precision oncology
Female
Amino Acid Sequence
Antineoplastic Agents/therapeutic use
GTP-Binding Protein alpha Subunits
Gq-G11/chemistry

GTP-Binding Protein alpha Subunits
Gq-G11/genetics

GTP-Binding Protein alpha Subunits
Gq-G11/metabolism

Humans
Melanoma/drug therapy
Melanoma/genetics
Melanoma/metabolism
Melanoma/pathology
Mutant Proteins/chemistry
Mutant Proteins/genetics
Mutant Proteins/metabolism
Pyridones/therapeutic use
Pyrimidinones/therapeutic use
Receptor
Fibroblast Growth Factor
Type 4/chemistry

Receptor
Fibroblast Growth Factor
Type 4/genetics

Receptor
Fibroblast Growth Factor
Type 4/metabolism

Signal Transduction
Uveal Neoplasms/drug therapy
Uveal Neoplasms/genetics
Uveal Neoplasms/metabolism
Uveal Neoplasms/pathology
FGFR4
GNAQ
mutation
Pyridones
Antineoplastic Agents
Pyrimidinones
Catalysis
Article
Inorganic Chemistry
medicine
Receptor
Fibroblast Growth Factor
Type 4

Physical and Theoretical Chemistry
Molecular Biology
Organic Chemistry
Fibroblast growth factor receptor 4
medicine.disease
lcsh:Biology (General)
lcsh:QD1-999
Personalized oncology
Cancer research
biology.protein
GTP-Binding Protein alpha Subunits
Gq-G11

Mutant Proteins
Zdroj: International Journal of Molecular Sciences, Vol 21, Iss 8021, p 8021 (2020)
International Journal of Molecular Sciences
International journal of molecular sciences, vol. 21, no. 21, pp. E8021
Volume 21
Issue 21
ISSN: 1661-6596
1422-0067
Popis: We report a case of an uveal melanoma patient with GNAQ p.Gly48Leu who responded to MEK inhibition. At the time of the molecular analysis, the pathogenicity of the mutation was unknown. A tridimensional structural analysis showed that G&alpha
q can adopt active and inactive conformations that lead to substantial changes, involving three important switch regions. Our molecular modelling study predicted that GNAQ p.Gly48Leu introduces new favorable interactions in its active conformation, whereas little or no impact is expected in its inactive form. This strongly suggests that GNAQ p.Gly48Leu is a possible tumor-activating driver mutation, consequently triggering the MEK pathway. In addition, we also found an FGFR4 p.Cys172Gly mutation, which was predicted by molecular modelling analysis to lead to a gain of function by impacting the Ig-like domain 2 folding, which is involved in FGF binding and increases the stability of the homodimer. Based on these analyses, the patient received the MEK inhibitor trametinib with a lasting clinical benefit. This work highlights the importance of molecular modelling for personalized oncology.
Databáze: OpenAIRE